ELIXA: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial 11 was the first-reported CVOT for GLP-1 RAs
Because GLP-1 medications deliver much higher levels of the hormone than the body naturally produces in the joints, researchers believe these drugs could potentially affect inflammation in those tissues
intramuscular route: count injections given Visit 4 (week 52) Anamnesis: record lifestyle habits and use of alcohol Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in level of happiness, and concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Record concomitant treatment Questionnaires: EuroQoL-5D, satisfaction and preferences Assessment of haemogram and serum vitamin B12 concentration Assessment of adverse effects Assess adherence to treatment: oral route count number of vials used
Some 2.4 million Brits are on some form of the weekly injections with the vast majority paying for them via private prescriptions
The best peptide for weight loss depends on individual needs and goals
Why the weight returns Your brain defends a target weight